Description
/* Reset & Base */
* {
box-sizing: border-box;
margin: 0;
padding: 0;
}
body {
font-family: ‘Inter’, -apple-system, BlinkMacSystemFont, ‘Segoe UI’, Roboto, Helvetica, Arial, sans-serif;
background: #fff;
color: #1e1e1e;
line-height: 1.6;
}
/* Utilities */
.sm-container {
max-width: 1300px;
margin: 0 auto;
padding: 20px 32px 60px;
width: 100%;
}
.sm-flex {
display: flex;
flex-wrap: wrap;
}
.sm-grid-2 {
display: grid;
grid-template-columns: 1fr 1fr;
gap: 40px;
}
.sm-grid-3 {
display: grid;
grid-template-columns: repeat(3, 1fr);
gap: 24px;
}
.sm-grid-4 {
display: grid;
grid-template-columns: repeat(4, 1fr);
gap: 20px;
}
/* Tabs */
.sm-tab-input {
display: none;
}
.sm-panel {
display: none;
}
#sm-tab-product:checked~.sm-tab-nav label[for=”sm-tab-product”],
#sm-tab-disclaimer:checked~.sm-tab-nav label[for=”sm-tab-disclaimer”] {
background: #F27444;
color: #fff;
border-color: #F27444;
box-shadow: 0 8px 20px rgba(242, 116, 68, 0.25);
}
#sm-tab-product:checked~.sm-product-panel {
display: block;
}
#sm-tab-disclaimer:checked~.sm-disclaimer-panel {
display: block;
}
/* FAQ */
.sm-faq summary::-webkit-details-marker {
display: none;
}
.sm-faq[open] .sm-plus {
transform: rotate(45deg);
}
/* Chips */
.sm-chip {
display: inline-block;
padding: 8px 16px;
border-radius: 999px;
background: #fff4ef;
border: 1px solid #ffd9cb;
color: #F27444;
font-weight: 600;
font-size: 0.9rem;
margin: 4px 6px 4px 0;
letter-spacing: 0.02em;
}
/* Cards & Hover */
.sm-card {
background: #fff;
border: 1px solid #f0e8e4;
border-radius: 28px;
padding: 28px;
transition: all 0.2s ease-in-out;
}
.sm-card:hover {
transform: translateY(-4px);
box-shadow: 0 20px 40px -12px rgba(0, 0, 0, 0.08);
border-color: #F27444;
}
.sm-card-glow {
background: linear-gradient(135deg, #fff 0%, #fff8f5 100%);
border: 1px solid #ffe1d6;
}
/* Specs Zebra */
.sm-spec-grid {
display: grid;
grid-template-columns: 1fr 1fr;
}
.sm-spec-item {
padding: 16px 24px;
border-bottom: 1px solid #f0e8e4;
background: #fff;
}
.sm-spec-item:nth-child(odd) {
background: #fcfaf9;
}
/* Responsive */
@media(max-width:768px) {
.sm-container {
padding: 20px 16px 40px;
}
.sm-grid-2,
.sm-grid-3,
.sm-grid-4 {
grid-template-columns: 1fr !important;
gap: 20px;
}
.sm-spec-grid {
grid-template-columns: 1fr;
}
.sm-tab {
width: 100% !important;
text-align: center !important;
}
.sm-hero-title {
font-size: 32px !important;
}
h2 {
font-size: 24px !important;
}
}
/* Misc */
.sm-tab {
font-size: 1rem;
padding: 12px 32px;
border-radius: 999px;
background: #fff;
border: 1px solid #e0d6d0;
color: #1e1e1e;
cursor: pointer;
font-weight: 600;
transition: all 0.2s;
user-select: none;
}
.sm-tab:hover {
background: #fff4ef;
border-color: #F27444;
}
.sm-hero-bg {
background: radial-gradient(ellipse at 70% 20%, rgba(242, 116, 68, 0.04) 0%, rgba(255, 255, 255, 0) 70%);
}
/* Reference list item hover */
.ref-item {
padding: 16px 20px;
background: #fff;
border-radius: 16px;
border: 1px solid #f0e8e4;
transition: all 0.2s ease-in-out;
}
.ref-item:hover {
border-color: #F27444;
box-shadow: 0 4px 12px rgba(242, 116, 68, 0.08);
}
.ref-item a {
color: #F27444;
font-weight: 700;
text-decoration: none;
}
.ref-item a:hover {
text-decoration: underline;
}
SaiyanMed Research Grade
Tirzepatide
Dual incretin receptor agonist (GIP / GLP-1) · research grade
Research-grade Tirzepatide is a synthetic 39-amino-acid dual GIP/GLP-1 receptor agonist supplied for laboratory study of incretin signaling, glucose-metabolism, and energy-balance research models. Each vial is lyophilized, ≥99% HPLC pure, MS-confirmed, and supported by publicly verifiable third-party COAs published in our Trust Center. For research use only — not for human or veterinary use.
≥99% HPLC
MS Confirmed
Third-Party COA
Lyophilized
Global Warehouse Fulfillment
Dual Incretin Axis
GIPR · GLP-1R
Designed for research models studying dual incretin-receptor signaling, glucose metabolism, energy balance, and comparative pharmacology against single (GLP-1) or triple (retatrutide) agonists.
39 AA
CAS 2023788-19-2
RUO
Research Context
Mechanistic Study Tool
Tirzepatide is positioned for mechanistic research into dual incretin-receptor signaling rather than human therapeutic or personal-use applications.
Incretin Signaling
Glucose Homeostasis
Energy Balance
What is Tirzepatide?
Tirzepatide (also designated P1206) is a synthetic 39-amino-acid peptide and the first-in-class dual agonist of the GIP and GLP-1 receptors — a single molecule that simultaneously activates both incretin receptors.
Structurally, it incorporates two α-aminoisobutyric acid (Aib) substitutions at positions 2 and 13 that confer resistance to DPP-4 degradation, and a C20 fatty-diacid side chain attached at Lys20 (via a γ-glutamate / mini-PEG linker) that drives >99% albumin binding and extends the half-life to approximately 5 days.
In research models, the dual GIP/GLP-1 mechanism is studied for incretin signaling, insulinotropic response, adipose-tissue signaling, and energy-metabolism endpoints. Tirzepatide is widely used as a reference dual-agonist for comparison against single (GLP-1) and triple (retatrutide) incretin agonists.
🧪 Research Applications
①
Dual Incretin Pharmacology
GIP + GLP-1R co-agonism, receptor interaction and internalization kinetics, and GIPR adipose signaling.
②
Glucose-Metabolism Research
Incretin-driven insulinotropic response and glucose-homeostasis research models.
③
Energy Balance & Adiposity
Adipose lipolysis, energy-expenditure, and fat-vs-lean-mass research models.
④
Hepatic / Metabolic-Liver
Hepatic steatosis and metabolic-liver research under dual incretin agonism.
⑤
Comparative Pharmacology
Dual (tirzepatide) vs single (GLP-1) vs triple (retatrutide) incretin receptor profiles.
⑥
PK / PD Profiling
Albumin-binding, half-life, receptor-occupancy, and biomarker-response studies.
📊 Quick Specs
Form: Lyophilized powder (white to off-white)
Purity: ≥99% by HPLC
Identity: MS molecular-weight confirmed
CAS Number: 2023788-19-2
Also Known As: P1206
Sequence Length: 39 amino acids
Molecular Formula: C225H348N48O68
Molecular Weight: ~4813.5 Da
Receptor Targets: GIPR + GLP-1R (dual agonist)
Modification: C20 fatty-diacid at Lys20; Aib at positions 2 & 13 (DPP-4 resistance); >99% albumin binding
Half-Life: ~5 days (research literature)
Peptide Type: Synthetic dual incretin receptor agonist
COA: Third-party lab tested — publicly verifiable
Manufacture: Lyophilized & QC-released in-house
Storage: −20°C sealed | 2–8°C reconstituted
Shelf Life: 24 months unopened (lyophilized)
VERIFIED
Certificate of Analysis
Third-Party Verification
Batches are independently tested by a third-party laboratory. The Certificate of Analysis documents HPLC purity and MS identity and is publicly verifiable at SaiyanMed Trust Center using the batch reference number shown on the COA.
Batch documentation should be reviewed before laboratory use. The batch reference must match the active product lot and vial specification.
📦 Storage & Handling
🧊 Storage
As with other incretin-based research peptides, store Tirzepatide lyophilized vials at −20°C, sealed, protected from light and moisture. After reconstitution: store at 2–8°C and use within 2–4 weeks (study-defined stability window). Avoid repeated freeze-thaw cycles. Do not use if the reconstituted solution is cloudy or contains visible particles.
💧 Reconstitution
Add 1–2 mL of sterile diluent slowly down the inside wall of the vial. Do not shake or vortex; swirl gently until fully dissolved. The resulting solution should be clear and colorless. Prepare working dilutions according to your laboratory protocol.
🚚 Fulfillment & Transit Notice
Fulfillment & shipping: Orders ship from the nearest available warehouse. US-based warehouse fulfillment is available for domestic US orders; international orders ship from the China warehouse with an estimated 7–14 day global delivery window.
Temperature in transit: Lyophilized peptides are stable at ambient temperature for the normal transit window. Brief temperature excursions during shipping do not compromise the lyophilized product. Refrigerate on arrival per the storage guidance above.
Customs handling: Cross-border research-chemical shipments may occasionally be subject to customs inspection or delay. This is a normal part of international scientific shipping and does not indicate a problem with the product.
Delays or holds: If a shipment is delayed beyond the estimated window or held in customs, contact us with your order reference. We will assist with tracking and, where applicable, arrange a reshipment in line with our shipping policy.
Damaged or incorrect items: Please inspect your order on arrival. If a vial is damaged or an item is incorrect, contact us within the period stated in our shipping policy, with photos, for prompt resolution.
⚠️
Research Use Only
This material is supplied only for qualified laboratory research and is not intended for human or veterinary use.
Research Use Only
Not for Human Consumption
SaiyanMed products are strictly for in vitro and in vivo laboratory research. They are not intended for diagnostic, therapeutic, medical, disease-prevention, consumer health, or personal use.
All SaiyanMed products are supplied for laboratory, scientific, and research use only. They are not for human consumption, medical treatment, diagnosis, disease prevention, or veterinary use.
✅ Buyer Confirmation
✓ You are a qualified researcher or acting under the supervision of one.
✓ Products will only be used for legitimate research purposes.
✓ Products are not evaluated by the FDA or any regulatory authority for human use.
✓ You assume responsibility for legal compliance, proper handling, storage, and disposal.
No Warranty: Products are sold “as is,” with no express or implied warranties regarding efficacy, safety, or suitability. Results in research may vary. SaiyanMed is not responsible for outcomes, interpretations, or conclusions drawn from any studies conducted using these products.
🛡️ General Safety & Handling
🚫 Not for Human Use
These compounds are for research only. Any off-label, personal, or clinical use is outside the intended scope.
🥽 PPE Required
Always use appropriate personal protective equipment, including gloves, lab coat, and eye protection.
🌡 Storage Compliance
Follow product-specific storage conditions to maintain identity, purity, and biological activity.
🗑 Proper Disposal
Dispose of all materials according to institutional biosafety, chemical waste, and hazardous material protocols.
🧾 Verify Quality
Verify batch identity, MS confirmation, HPLC purity, and COA status before research use.
⚖ Legal Compliance
Researchers are responsible for lawful purchase, possession, storage, and use in their jurisdiction.
💬 Frequently Asked Questions
What is Tirzepatide used for?+
Tirzepatide is supplied strictly as a research reference compound for in vitro and in vivo laboratory study of dual GIP/GLP-1 incretin-receptor signaling and metabolic research models. It is not for human or veterinary use.
How is purity verified?+
Published lots are tested to ≥99% by analytical HPLC, with identity confirmed by mass spectrometry. A third-party COA is published and independently verifiable.
How should it be stored?+
Store Tirzepatide lyophilized vials at −20°C. After reconstitution, store at 2–8°C and use within 2–4 weeks. Avoid repeated freeze-thaw cycles.
How is Tirzepatide different from Retatrutide?+
Tirzepatide is a dual GIP/GLP-1 receptor agonist; Retatrutide adds a third receptor arm (glucagon/GCGR), making it a triple agonist. Both are studied as incretin research tools.
Where does it ship from?+
From the nearest available warehouse — US-based warehouse fulfillment for US orders; international orders from the China warehouse (est. 7–14 days).
Is this intended for human use?+
No. This material is strictly for laboratory research use only and is not intended for human consumption, diagnosis, treatment, disease prevention, or personal use.
📚 References
International Journal of Obesity (Nature, 2025):
Effects of tirzepatide on weight management in patients with and without diabetes: a systematic review and meta-analysis.
Volume 49, pages 2415–2425.
View at Nature ↗
Expert Opinion on Drug Safety (Taylor & Francis, 2025):
Hoffmann K, Michalak M, Rizzo M, et al.
The efficacy and safety of dual GIP/GLP1 receptor agonists (tirzepatide) in diabetes and obesity: a systematic review and network meta-analysis.
Pages 1031-1046. PROSPERO-registered.
View at Taylor & Francis Online ↗
Diabetologia (Springer, 2024):
Karagiannis T, Malandris K, Avgerinos I, et al.
Subcutaneously administered tirzepatide vs semaglutide for adults with type 2 diabetes: a systematic review and network meta-analysis of randomised controlled trials.
67:1206–1222. DOI: 10.1007/s00125-024-06144-1.
View at PMC ↗
European Journal of Pharmacology (ScienceDirect, 2025):
The efficacy and safety of glucagon-like peptide-1 receptor agonists in non-diabetic adults with overweight/obesity: An umbrella review of systematic reviews and meta-analyses.
PROSPERO: CRD42024603661.
View at ScienceDirect ↗
Molecules (MDPI, 2022):
Chavda VP, et al.
Tirzepatide, a New Era of Dual-Targeted Treatment for Diabetes and Obesity: A Mini-Review.
27(13):4315.
View at MDPI (open access) ↗
PMC / MDPI (2023):
Novel Dual Incretin Receptor Agonists in the Spectrum of Metabolic Diseases with a Focus on Tirzepatide: Real Game-Changers or Great Expectations? A Narrative Review.
Published: 2023-07-01.
View at PMC ↗
Nature Reviews Endocrinology (2026):
Causes and consequences of discontinuation of GLP1RAs or tirzepatide.
Published: 2026-05-21.
View at Nature ↗





Reviews
There are no reviews yet.